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Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell 
Carcinoma Do Not reASSURE 
The ASSURE trial (NCT00326898) was designed to evaluate the ability, in the adjuvant 
setting, of two oral antiangiogenic agents to prevent disease recurrence in patients with high-
risk localized renal cell carcinoma (RCC) [1]. 
The trial randomly assigned 1943 patients with completely resected RCC to 1-yr treatment 
with sorafenib (400 mg twice daily, n = 649), sunitinib (50 mg/day for 4 wk of every 6 wk, n 
= 647), or a placebo (n = 647). The primary endpoint was disease-free survival (DFS). The 
study was designed to detect a 25% reduction in the hazard ratio (HR), corresponding to an 
improvement of 1.9 yr in median DFS. 
An interim analysis using 62% of the anticipated data showed that 5-yr DFS rates varied 
slightly from 52.8% to 55.8% across the three arms, yielding HRs of 0.98 for sorafenib and 
1.01 for sunitinib compared to placebo. Similarly, the 5-yr overall survival ranged from 
76.9% to 80.7%, yielding HRs of 0.93 for sorafenib and 1.10 for sunitinib compared to 
placebo. The investigators also performed an analysis for a clear-cell RCC subgroup (80% of 
the patients in each arm) and found HR values of approximately 1 in each group. Therefore, 
the Data and Safety Monitoring Board recommended that the trial be terminated with 
immediate release of the results. The study findings suggest that neither sorafenib nor 
sunitinib offers benefits greater than those of placebo. For this reason, patients with locally 
advanced RCC should not receive adjuvant treatment with either sorafenib or sunitinib. 
A negative trial always raises concerns regarding contamination, power, or design biases. 
First, patient dropout because of poor tolerance is a very important flaw in every adjuvant 
trial. Thus, the expected improvements were shifted slightly to 4.9 yr for placebo and 6.5 yr 
for treatment. In fact, 70% and 63% of patients experienced grade 3 or higher adverse events 
with sorafenib and sunitinib, respectively (vs 24% in the placebo arm). However, this 
protocol amendment did not underpower the trial because accrual was higher than expected 
(from 444 to 641 patients per arm) and the proportion of high-risk patients according to the 
University of California-Los Angeles integrated staging system [2] shifted from 30% to 50%, 
allowing a consistent 25% difference in the PFS. In addition, toxicity was well tolerated for 
dose reduction followed by dose escalation. As a result, patients could receive a median of 
eight and nine cycles in the tyrosine kinase inhibitor (TKI) and placebo arms, respectively. 
To evaluate the extent of the impact of dose reduction on outcomes, subgroup analyses for 
patients who could tolerate a full TKI dose are ongoing. 
Second, the 1-yr duration for adjuvant treatment might be questioned and could be 
considered insufficient. Upcoming Sorce (placebo vs sorafenib 1 or 3 yr, NCT00492258) and 
Atlas (placebo versus axitinib for at least 1 yr and up to 3 yr, NCT01599754) trials will 
probably address this issue. 
Finally, all patients in adjuvant trials are selected using risk stratification tools based on TNM 
staging, pathology, and performance status. More elaborate tools involving genomic 
sequencing and molecular biology of the tumors and the host are currently lacking. Analysis 
of tissue and blood samples collected from all trials might provide us with an insight into 
how biology could help to improve patient selection for adjuvant therapy because of poor 
“biological” prognosis. 
In conclusion, while awaiting the results of ongoing adjuvant trials, we should keep in mind 
that use of TKIs to prevent suspected recurrence of micrometastases in high-risk RCC 
patients may be a dead end, as has been demonstrated for colon [3,4] and breast cancers [5]. 
We should consider investigation of immunologic therapies, such as PD1 and PDL1 
antagonists, for this setting. 
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